{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:15:01Z","timestamp":1766870101457,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.tjog.2017.04.006","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T15:39:55Z","timestamp":1496849995000},"page":"302-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A\u00a0retrospective, single institute study"],"prefix":"10.1016","volume":"56","author":[{"given":"Chui-Na","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui-Nguk","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Shing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.tjog.2017.04.006_bib1","first-page":"S161","article-title":"Carcinoma of the ovary. 26th annual report on the results of treatment in gynecologic cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2017.04.006_bib2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2017.04.006_bib3","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2017.04.006_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(01)00188-5","article-title":"A\u00a0randomized trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer","volume":"38","author":"Gore","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ijgc-00009577-200801000-00008","article-title":"A\u00a0feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy","volume":"18","author":"Comander","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjc.6602427","article-title":"Phase I\/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer","volume":"92","author":"Baur","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1525-1438.2007.00994.x","article-title":"Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer","volume":"18","author":"Verborg","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10147-010-0094-1","article-title":"Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer","volume":"15","author":"Watanabe","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.tjog.2017.04.006_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2017.04.006_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2017.04.006_bib11","first-page":"e154","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","volume":"12","author":"Handolias","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.tjog.2017.04.006_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib14","unstructured":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE). http:\/\/ctep.cancer.gov."},{"key":"10.1016\/j.tjog.2017.04.006_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.tjog.2017.04.006_bib16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","article-title":"Redefining the target: chemotherapeutics as antiangiogenics","volume":"19","author":"Miller","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2017.04.006_bib17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/apm.12201","article-title":"Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?","volume":"122","author":"Norrby","year":"2014","journal-title":"APMIS"},{"key":"10.1016\/j.tjog.2017.04.006_bib18","first-page":"2731","article-title":"Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.tjog.2017.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-7-65","article-title":"Cyclophosphamide \u201cmetronomic\u201d chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer","volume":"7","author":"Samaritani","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2017.04.006_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","article-title":"Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"107","author":"Chura","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2017.04.006_bib21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2017.04.006_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"79","author":"Sanchez-Munoz","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.tjog.2017.04.006_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3802\/jgo.2013.24.3.258","article-title":"The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer","volume":"24","author":"Barber","year":"2013","journal-title":"J\u00a0Gynecol Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455917300761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455917300761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:15:54Z","timestamp":1760897754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455917300761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1028455917300761"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2017.04.006","relation":{},"ISSN":["1028-4559"],"issn-type":[{"type":"print","value":"1028-4559"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A\u00a0retrospective, single institute study","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2017.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}